Table 3.
Associations between tea drinking habits and breast cancer risk stratified by intensity, frequency, starting age, menopausal, and ER status.
| Non-drinkersa | Regular tea drinkers | Regular green tea drinkers | ||||
|---|---|---|---|---|---|---|
| Cases/controls | OR(95%CI)b | Cases/controls | OR(95%CI)b | Cases/controls | OR(95%CI)b | |
| Tea consumption | 317/355 | 1.00 | 439/434 | 1.01 (0.78–1.31) | 122/97 | 1.20 (0.80–1.78) |
| Intake (cups/d) | ||||||
| <1 | 245/241 | 0.96 (0.67–1.37) | 40/24 | 1.08 (0.52–2.25) | ||
| 1~3 | 136/112 | 0.95 (0.68–1.31) | 53/49 | 1.20 (0.71–2.03) | ||
| >3 | 43/58 | 1.25 (0.85–1.84) | 26/20 | 1.53 (0.71–3.28) | ||
| p-trend | 0.48 | 0.24 | ||||
| Intake years(y) | ||||||
| ≤15 | 245/241 | 1.03 (0.77–1.38) | 75/57 | 1.41 (0.87–2.27) | ||
| ≤30 | 136/112 | 1.27 (0.87–1.86) | 30/21 | 1.00 (0.48–2.07) | ||
| >30 | 43/58 | 0.66 (0.39–1.14) | 11/13 | 0.85 (0.29–2.50) | ||
| p-trend | 0.81 | 0.46 | ||||
| Cumulative tea consumption (cup-years) | ||||||
| ≤9 | 136/132 | 1.03 (0.72–1.48) | 38/23 | 1.42 (0.67–3.01) | ||
| 10–29 | 119/131 | 0.88 (0.62–1.26) | 35/33 | 1.19 (0.67–2.10) | ||
| ≥30 | 160/137 | 1.24 (0.88–1.76) | 40/31 | 1.29 (0.71–2.32) | ||
| p-trend | 0.44 | 0.27 | ||||
| Menopausal status | ||||||
| Premenopausal | 131/136 | 1.00 | 153/169 | 0.62 (0.40–0.97) | 51/43 | 0.69 (0.35–1.35) |
| Postmenopausal | 186/219 | 1.00 | 286/265 | 1.40 (1.00–1.96) | 71/54 | 1.82 (1.07–3.10) |
| Estrogen receptor status | ||||||
| ER+ | 185/355 | 1.00 | 259/434 | 0.94 (0.69–1.28) | 67/97 | 0.99 (0.60–1.63) |
| ER− | 54/355 | 1.00 | 82/434 | 1.16 (0.74–1.84) | 29/97 | 2.03 (1.08–3.84) |
| Starting age of drinking | ||||||
| ≤20 | 41/59 | 0.65 (0.37–1.16) | 5/11 | 0.44 (0.11–1.83) | ||
| 20~50 | 283/275 | 1.05 (0.79–1.40) | 90/70 | 1.24 (0.80–1.92) | ||
| ≥50 | 100/76 | 1.26 (0.82–1.96) | 21/9 | 1.93 (0.73–5.08) | ||
| p-trend | 0.36 | 0.17 | ||||
a
Non-drinkers referred to those who did not drink any kind of tea.
b
Adjusted for age at interview, age at menarche, age at first birth, parity, hormone replacement therapy, first-degree family history and body mass index.